June 12, 2020 / 1:14 PM / 21 days ago

BRIEF-Novo Nordisk: Semaglutide 2.4 Mg Shows Superior Weight Loss Versus Placebo In Phase 3 Trials

June 12 (Reuters) - Novo Nordisk A/S:

* REG-SEMAGLUTIDE 2.4 MG SHOWS SUPERIOR WEIGHT LOSS VERSUS PLACEBO IN THE PHASE 3 TRIALS STEP 2 AND STEP 3, THEREBY SUCCESSFULLY COMPLETING THE PROGRAMME

* ANNOUNCED HEADLINE RESULTS FROM FINAL TWO PHASE 3A CLINICAL TRIALS INVESTIGATING ONCE-WEEKLY SUBCUTANEOUS (SC) SEMAGLUTIDE 2.4 MG FOR WEIGHT MANAGEMENT

* TRIAL MET BOTH PRIMARY ENDPOINTS

* IN BOTH STEP 2 AND STEP 3, SC SEMAGLUTIDE 2.4 MG APPEARED TO HAVE A SAFE AND WELL-TOLERATED PROFILE, CONSISTENT WITH PREVIOUS FINDINGS

* MOST COMMON ADVERSE EVENTS AMONG PEOPLE TREATED WITH SC SEMAGLUTIDE 2.4 MG WERE GASTROINTESTINAL EVENTS Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below